

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;

(b) complements of any of the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974;

(c) sequences having at least 90% identity to any one of the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974; and

(d) degenerate variants of any one of the sequences provided in SEQ ID NOs:10,486 - 10,536; SEQ ID NOs:10,537 - 10,580; SEQ ID NOs:10,581 - 10,596; SEQ ID NO:10,597; SEQ ID NO:10,845; SEQ ID NO:10,846; SEQ ID NO:10,970; SEQ ID NO:10,971; SEQ ID NO:10,972; SEQ ID NO:10,973; and SEQ ID NO:10,974.

2. (Withdrawn) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences encoded by a polynucleotide of claim 1; and

(b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. (Withdrawn) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.

4. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 3.

5. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.

6. (Currently Amended) A method for detecting the presence of lymphoma in a patient, comprising the steps of:

(a) obtaining a ~~biological lymphoid sample from the a patient suspected of having lymphoma;~~

(b) contacting the biological sample with a binding agent that binds to ~~a the~~ polypeptide of SEQ ID NO:9611 ~~encoded by the nucleic acid comprising the sequence set forth in SEQ ID NO: 10,582 or a complement thereof;~~

(c) detecting in the sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the binding agent; and

(d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control sample comprising lymphoid tissue from a subject without lymphoma to a predetermined cut-off value, wherein an amount of polypeptide detected in step (c) that is greater than the predetermined cut-off values ~~amount of polypeptide in the control sample~~ is indicative of the presence of lymphoma in the patient.

7. (Withdrawn) A fusion protein comprising at least one polypeptide according to claim 2.

8. (Withdrawn) The fusion protein of claim 7, further comprising Ra12.

9. (Withdrawn) The fusion protein of claim 7, further comprising a His tag.

10. (Withdrawn) An oligonucleotide that hybridizes to the polynucleotides of claim 1.

11. (Withdrawn) A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polypeptide according to claim 1, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

12. (Withdrawn) An isolated T cell population, comprising T cells prepared according to the method of claim 11.

13. (Withdrawn) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 12; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

14. (Withdrawn) A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 13.

15. (Withdrawn) A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 13.

16. (Withdrawn) A method for determining the presence of a cancer in a patient, comprising the steps of:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide according to claim 10;

- (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and

- (d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient.

17. (Withdrawn) A diagnostic kit comprising at least one oligonucleotide according to claim 10.

18. (Withdrawn) A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group.

19. (Withdrawn) A method for inhibiting the development of a cancer in a patient, comprising the steps of:

- (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; and (iii) antigen presenting cells that express a polypeptide of claim 2, such that T cell proliferate;

- (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

20. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

- (a) sequence provided in SEQ ID NO:10,469 or SEQ ID NO:10,470;

(b) complements of the sequence provided in SEQ ID NO:10,469 or SEQ ID NO:10,470;

(c) sequences having at least 90% identity to SEQ ID NO:10,469 or SEQ ID NO:10,470; and

(d) degenerate variants of SEQ ID NO:10,469 or SEQ ID NO:10,470.

21. (Withdrawn) An isolated polypeptide comprising an amino acid sequence provided in SEQ ID NO:10,471 or SEQ ID NO:10,474.

22. (Withdrawn) An isolated polynucleotide comprising a sequence selected from the group consisting of:

(a) sequence provided in SEQ ID NO:10,480;

(b) complements of the sequence provided in SEQ ID NO:10,480;

(c) sequences having at least 90% identity to a sequence of SEQ ID NO:10,480; and

(d) degenerate variants of a sequence provided in SEQ ID NO:10,480.

23. (Withdrawn) An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:10,481.

24. (Withdrawn) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences encoded by a polynucleotide of claim 20 or 22; and

(b) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 20 or 22.

25. (Withdrawn) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) sequences provided in any one of SEQ ID NOs:10,599 - 10,819; and

(b) sequences provided in any one of SEQ ID NOs:10,820 - 10,842.

26. (Withdrawn) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) sequences provided in any one of SEQ ID NOs:10,849 - 10,908; and
- (b) sequences provided in any one of SEQ ID NOs:10,909 - 10,968.

27. (New) The method of claim 6, wherein the binding agent is an antibody.

28. (New) The method of claim 6, wherein the binding agent is a monoclonal antibody.

29. (New) A method for detecting the presence of lymphoma in a patient, comprising the steps of:

- (a) obtaining a B-cell sample from a patient suspected of having lymphoma;
- (b) contacting the biological sample with a binding agent that binds to the polypeptide of SEQ ID NO:9611;
- (c) detecting in the sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the binding agent; and
- (d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control B-cell sample from a subject without lymphoma, wherein an amount of polypeptide detected in step (c) that is greater than the amount of polypeptide in the control sample is indicative of the presence of lymphoma in the patient.

30. (New) The method of claim 29, wherein the binding agent is an antibody.

31. (New) The method of claim 29, wherein the binding agent is a monoclonal antibody.

32. (New) A method for detecting the presence of lymphoma in a patient, comprising the steps of:

- (a) obtaining a lymph node sample from a patient suspected of having lymphoma;
- (b) contacting the biological sample with a binding agent that binds to the polypeptide of SEQ ID NO:9611;
- (c) detecting in the sample an amount of the polypeptide of SEQ ID NO:9611 that binds to the binding agent; and
- (d) comparing the amount of polypeptide detected in step (c) to the amount of polypeptide of SEQ ID NO:9611 in a control lymph node sample from a subject without lymphoma, wherein an amount of polypeptide detected in step (c) that is greater than the amount of polypeptide in the control sample is indicative of the presence of lymphoma in the patient.

33. (New) The method of claim 32, wherein the binding agent is an antibody.

34. (New) The method of claim 32, wherein the binding agent is a monoclonal antibody.